Profound Medical CORP 8-K filings

New data from the CAPTAIN trial indicates Profound Medical's TULSA Procedure preserves penile length better than robotic radical prostatectomy at one month post-treatment.

Profound Medical Corp. announced plans to release its second quarter 2026 financial results on August 6, 2026, followed by a conference call.

Profound Medical Corp. announced its TULSA Procedure will be featured in multiple presentations at the Society of Robotic Surgery Annual Meeting.

Profound Medical Corp. shareholders elected eight directors and approved the company's long-term incentive plan.

Profound Medical Corp. announced its TULSA Procedure will be featured in four oral presentations at the American Urological Association's Annual Meeting, alongside an initiative to explore PSMA PET integration for enhanced planning and monitoring.

Profound Medical Corp. will release its first quarter 2026 financial results after market close on May 7, 2026.

Profound Medical Corp. announced its management will present a business update at the 2026 Bloom Burton & Co. Healthcare Investor Conference on April 22, 2026.

Profound Medical Corp. announces its TULSA Procedure will be prominently featured in multiple presentations at the 2026 Society of Interventional Radiology Annual Scientific Meeting.

Profound Medical Corp. announced that Texas Prostate achieved its 100th TULSA Procedure, marking significant adoption and clinical success.

Profound Medical's CAPTAIN trial demonstrates the TULSA Procedure's superior safety and functional outcomes compared to robotic radical prostatectomy for prostate cancer.

Profound Medical Corp. announced record fourth-quarter and full-year 2025 financial results, driven by strong TULSA-PRO sales and strategic global expansion.

Profound Medical Corp. announced it will release its fourth quarter and full year 2025 financial results on March 5, 2026, followed by a conference call.

Profound Medical Corp. received the 2025/2026 Mount Logan Award from INOVAIT for its TULSA Procedure, recognizing significant milestones and global expansion.

Profound Medical Corp. announced PRO FAMILIA Specialist Hospital in Poland completed its 500th Sonalleve Procedure, expanding non-surgical care for women's health.

Mount Sinai Hospital becomes the first in Metro New York to offer Profound Medical's TULSA-PRO system for incision-free, MRI-guided prostate treatment.

Profound Medical Corp. announced its TULSA-PRO installed base reached 78 systems by year-end 2025, surpassing its goal of 75, with a sales pipeline of 97 new systems.

Profound Medical Corp. announced Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using the TULSA-PRO system, marking a significant commercial milestone.

Profound Medical Corp. announced the closing of a private placement, raising $6.45 million through the sale of 921,428 common shares to Canadian investors.

Profound Medical Corp. announced a $36 million registered direct offering and a $4 million private placement to fund sales, R&D, and strategic initiatives.

Profound Medical Corp. announced the launch of its TULSA-AI Volume Reduction module for benign prostatic hyperplasia, significantly expanding its market potential.

Profound Medical Corp. announced an exclusive distribution and supply agreement with Getz Healthcare to bring its TULSA-PRO system to Australia and New Zealand.

Profound Medical Corp. has signed an exclusive distribution agreement with Al Faisaliah Medical Systems Co. to bring its TULSA-PRO and Sonalleve technologies to Saudi Arabia.

Profound Medical Corp. has regained exclusive distribution rights for its TULSA-PRO system in Canada from Knight Therapeutics Inc.

Profound Medical Corp. announced preliminary unaudited third-quarter 2025 revenues are expected to reach a record $5.2 million to $5.3 million, marking significant year-over-year growth.

Profound Medical Corp. reported flat revenue of $2.2 million and a widened net loss of $15.7 million for Q2 2025, despite growing TULSA-PRO system utilization and pipeline.

Profound Medical Corp. announced a landmark partnership with former NFL safety Leonard Wheeler, who successfully underwent the TULSA procedure for prostate cancer, to serve as a Global Ambassador for its TULSA-PRO system.

Profound Medical Corp. held its 2025 Annual General and Special Meeting, where shareholders voted on the election of directors, appointment of auditors, and approval of unallocated options under the share option plan.

Profound Medical Corp. announced an 82% increase in revenue for the first quarter of 2025, driven by strong adoption of its TULSA-PRO technology.

Profound Medical's TULSA procedure demonstrates statistically significant improvements in post-operative experience compared to robotic radical prostatectomy in the CAPTAIN trial.

Profound Medical Corp. is positioning its TULSA-PRO system as a leading treatment for prostate ablation, both for malignant and benign conditions, highlighting clinical trial results, patient satisfaction, and new AI-powered software enhancements.